title: [Abnormal expression of insulin-like growth factor-II and intervening of its mRNA transcription in the promotion of HepG2 cell apoptosis].
abstract: OBJECTIVE
  To explore the expression and pathological features of insulin-like growth factor-II (IGF-II) in tissues and sera of hepatocellular carcinoma (HCC) patients and the siRNA-mediated inhibition of IGF-II mRNA transcription in human HepG2 cells.
  
  
  METHODS
  From December 2009 to August 2010, the self-control HCC, paracancerous and distal cancerous tissues were collected to analyze the expression of IGF-II. The serum levels of IGF-II expression were detected for pathological features. IGF-II expression in HepG2 cells was intervened by siRNA. IGF-II mRNA or IGF-II level and analyzed by reverse transcription-polymerase chain reaction (RT-PCR), real-time PCR or enzyme-linked immunosorbent assay (ELISA). And the ratio of cell apoptosis was analyzed by EdU/Hoechst33342.
  
  
  RESULTS
  The levels of IGF-II expression in HCC tissues at mRNA (100%, 30/30) or protein (83.3%, 25/30) were significantly higher (P < 0.01) than those in para-cancerous (46.7%, 53.3%) or distal cancerous tissues (0, 0). The serum level of IGF-II was significantly higher in HCC patients (3.74 ± 0.67) ng/L than that in cases with benign liver diseases (1.93 ± 0.17) ng/L and controls (1.14 ± 0.14) ng/L (P < 0.001). The expression of IGF-II in the HCC group was associated with HBV infection (t = 5.390, P < 0.001). After siRNA transfection, the expression of IGF-II decreased significantly in HepG2 cells at mRNA or protein levels. The down-regulated expression of IGF-II was dependent on the dose and time of IGF-II siRNA. And the apoptotic index of HepG2 cells and the sensitivity to adriamycin both increased.
  
  
  CONCLUSIONS
  The expression of IGF-II is closely associated with the progression of HCC. And the intervening of its transcription may promote apoptosis and sensitize to adriamycin.
authors.affiliation: Nantong University, Nantong, China.
authors.forename: Zhi-zhen
authors.initials: ZZ
authors.lastname: Dong
authors.forename: Min
authors.initials: M
authors.lastname: Yao
authors.forename: Jing
authors.initials: J
authors.lastname: Qian
authors.forename: Xiao-di
authors.initials: XD
authors.lastname: Yan
authors.forename: Jie
authors.initials: J
authors.lastname: Chen
authors.forename: Mei-juan
authors.initials: MJ
authors.lastname: Yan
authors.forename: Ning-hua
authors.initials: NH
authors.lastname: Yao
authors.forename: Deng-fu
authors.initials: DF
authors.lastname: Yao
mesh_terms: D017209:Apoptosis / Q000235:genetics; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000473:pathology; D005260:Female; D056945:Hep G2 Cells; D006801:Humans; D007335:Insulin-Like Growth Factor II / Q000378:metabolism*; D008113:Liver Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000235:genetics; D034741:RNA, Small Interfering; D014158:Transcription, Genetic
chemical_list: C035170:IGF2 protein, human; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D007335:Insulin-Like Growth Factor II